Article

JOURNAL MENU
Cover
Journal Cover Page

RGUHS Nat. J. Pub. Heal. Sci Vol: 14  Issue: 2 eISSN:  pISSN

Original Article

Efficacy and Safety of Meropenem with Clavulanic acid in the Treatment of Multi-drug Resistant and Extensively-drug Resistant Tuberculosis

Kishor Chandra Mohanty1 , Salil Bendre2 ,Nikhil Sarangdhar3 , Racchana d Fadia4

1 Director Professor & Head,

2Associate Professor,

3Senior Registrar,

4Clinical Research Assistant,

Deptt. of Respiratory Diseases, K.J. Somaiya Medical College, Mumbai

Year: 2011, Volume: 1, Issue: 2, Page no. 27-32,
Views: 581, Downloads: 6
Licensing Information:
CC BY NC 4.0 ICON
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0.
Abstract

Study objectives : To study the efficacy and safety of Meropenem with clavulanic acid in Extensively Drug resistant and Multi- Drug resistant Tuberculosis. Design : An open labelled study. Setting : A community teaching hospital cum Medical College with 400 beds in Mumbai, with 40 beds for TB and Chest diseases, which acts as a ** *** **** tertiary referral institute for several specialities. The institute also has a D.O.T. centre as well as D.M.C. accredited and managed by R.N.T.C.P. Patients and Interventions : 26 patients of sputum positive pulmonary tuberculosis with culture and drug susceptibility reports of Extensive drug resistance (XDR) or Multi-drug resistance (MDR) were given Intravenous Meropenem with clavulanic acid once daily . Sputum smear was done every 15 days. Results : . 21 out of 26 patients (80.8%) turned sputum negative within 60 days. Sputum conversion was seen in 9.1%, 45.5%, 54.6% and 90.9% of MDR-TB patients and in 36.6%, 56.6%, 63.2% and 73.3% of XDR-TB patients at 15, 30, 45 and 60 days of treatment respectively. Conclusion : Meropenem along with clavulanic acid was found to be successful as a additional drug in the treatment of Extensively drug resistant and Multi-Drug resistant Tuberculosis . The success rate of this therapeutic combination for early sputum conversion, could be used for patients who are willing to be hospitalised, and will also provide hope in the era where second line anti- tuberculosis drugs are expensive, prevalence rates high and success rates low

<p>Study objectives : To study the efficacy and safety of Meropenem with clavulanic acid in Extensively Drug resistant and Multi- Drug resistant Tuberculosis. Design : An open labelled study. Setting : A community teaching hospital cum Medical College with 400 beds in Mumbai, with 40 beds for TB and Chest diseases, which acts as a ** *** **** tertiary referral institute for several specialities. The institute also has a D.O.T. centre as well as D.M.C. accredited and managed by R.N.T.C.P. Patients and Interventions : 26 patients of sputum positive pulmonary tuberculosis with culture and drug susceptibility reports of Extensive drug resistance (XDR) or Multi-drug resistance (MDR) were given Intravenous Meropenem with clavulanic acid once daily . Sputum smear was done every 15 days. Results : . 21 out of 26 patients (80.8%) turned sputum negative within 60 days. Sputum conversion was seen in 9.1%, 45.5%, 54.6% and 90.9% of MDR-TB patients and in 36.6%, 56.6%, 63.2% and 73.3% of XDR-TB patients at 15, 30, 45 and 60 days of treatment respectively. Conclusion : Meropenem along with clavulanic acid was found to be successful as a additional drug in the treatment of Extensively drug resistant and Multi-Drug resistant Tuberculosis . The success rate of this therapeutic combination for early sputum conversion, could be used for patients who are willing to be hospitalised, and will also provide hope in the era where second line anti- tuberculosis drugs are expensive, prevalence rates high and success rates low</p>
Keywords
Extensively Drug resistant tuberculosis, Multi-Drug resistant tuberculosis, Meropenem, clavulanic acid, Culture and drug susceptibility testing , Sputum conversion
Downloads
  • 1
    FullTextPDF
Article

none

Supporting File
No Pictures
References

none

We use and utilize cookies and other similar technologies necessary to understand, optimize, and improve visitor's experience in our site. By continuing to use our site you agree to our Cookies, Privacy and Terms of Use Policies.